Special considerations for the diagnosis and treatment of invasive pulmonary aspergillosis
The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The diagnosis and treatment of invasive pulmonary aspergillosis (IPA) are ongoing challenges in clinical practice. While important advances have recently been made, including enhanced diagnostic modalities as well as novel therapeutic and prophylactic options, more effective options are urgently needed as the population of immunocompromised patients continues to expand. Areas covered: In this paper, we review novel approaches to diagnosis of IPA, including multiplex PCR, Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry and provide a detailed review of the extended-spectrum triazole isavuconazole, which was approved in 2015 to treat IPA. Expert commentary: We explore burgeoning approaches to diagnosis, including the lateral flow assay, volatile organic compounds, and artificial olfactory technology, as well as novel antifungal agents to treat IPA such as SCY-078 and F901318.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In these patients, with impaired immune function, Aspergillus growth in the lung leads to tissue destruction, angio-invasion, a septic state in its final phase and sometimes haemoptysis [98].”
From Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision (2017) · cites this paper as [98]
Citations
Cites
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw326 · Cited by 2,926 · cited 3×
“with prolonged neutropenia, HSCT, SOT, or T-cell deficiencies [7,8].”
BackgroundSelf-citationWalsh, T. J., Anaissie, E. J., Denning, D. W., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Segal, B. H., Steinbach, W. J., Stevens, D. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/525258 · Cited by 2,706 · cited 2×
“a high index of suspicion for early diagnosis [8].”
BackgroundSelf-citationElectronic Nose: Current Status and Future Trends
Röck, F., Barsan, N., & Weimar, U. (2008) · Chemical Reviews · doi:10.1021/cr068121q · Cited by 1,437 · cited 1×
“inexpensive and noninvasive method to diagnose IPA [124].”
MethodLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management
Denning, D. W., Cadranel, J., Beigelman-Aubry, C., Ader, F., Chakrabarti, A., Blot, S., Ullmann, A. J., Dimopoulos, G., & Lange, C. (2016) · European Respiratory Journal · doi:10.1183/13993003.00583-2015 · Cited by 1,030 · cited 1×
“Chronic pulmonary aspergillosis represents a different form of pulmonary disease and includes conditions such as chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, Aspergillus nodule, simple aspergilloma, and tracheobronchial aspergillosis [3,19].”
BackgroundMaertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01159-9 · Cited by 1,001 · cited 2×
“Successful outcomes have been reported for patients with IA and renal impairment [90].”
BackgroundThe clinical spectrum of pulmonary aspergillosis
Kosmidis, C., & Denning, D. W. (2015) · Thorax · doi:10.1136/thoraxjnl-2014-206291 · Cited by 850
Emergence of Azole Resistance in Aspergillus fumigatus and Spread of a Single Resistance Mechanism
Snelders, E., van der Lee, H. A. L., Kuijpers, J., Rijs, A. J. M. M., Varga, J., Samson, R. A., Mellado, E., Donders, A. R. T., Melchers, W. J. G., & Verweij, P. E. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050219 · Cited by 727
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704 · cited 1×
“In addition to this, isavuconazole has been evaluated in a randomized, double-blind noninferiority trial for the treatment of IA and, in a separate, open-label study in the treatment of mucormycosis [90,91].”
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
Verweij, P. E., Chowdhary, A., Melchers, W. J. G., & Meis, J. F. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ885 · Cited by 561
Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial
Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m13-2508 · Cited by 514 · cited 1×
“A randomized trial of combination therapy that compared voriconazole plus the echinocandin anidulafungin versus voriconazole monotherapy in patients with IA showed that combination therapy improved survival for the subpopulation of patients in whom the diagnosis was confirmed by serum and/or BAL fluid GMA [132].”
ResultSelf-citationHow to bolster the antifungal pipeline
Denning, D. W., & Bromley, M. J. (2015) · Science · doi:10.1126/science.aaa6097 · Cited by 481
Antifungal Therapy Decreases Sensitivity of theAspergillus Galactomannan Enzyme Immunoassay
Marr, K. A., Laverdiere, M., Gugel, A., & Leisenring, W. (2005) · Clinical Infectious Diseases · doi:10.1086/429921 · Cited by 471
Evaluation of a (1→3)-β- d -Glucan Assay for Diagnosis of Invasive Fungal Infections
Pickering, J. W., Sant, H. W., Bowles, C. A. P., Roberts, W. L., & Woods, G. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.12.5957-5962.2005 · Cited by 379
Patterson, T. F., Thompson, G. R., Denning, D. W., Fishman, J. A., Hadley, S., Herbrecht, R., Kontoyiannis, D. P., Marr, K. A., Morrison, V. A., Nguyen, M. H., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw444 · Cited by 373 · cited 1×
“immunocompromised hosts, and are often associated with tissue destruction, angioinvasion, and hemoptysis [22,23].”
BackgroundSelf-citationThe Changing Epidemiology of Invasive Fungal Infections
Enoch, D. A., Yang, H., Aliyu, S. H., & Micallef, C. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-6515-1_2 · Cited by 370
Molecular and Nonmolecular Diagnostic Methods for Invasive Fungal Infections
Arvanitis, M., Anagnostou, T., Fuchs, B. B., Caliendo, A. M., & Mylonakis, E. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00091-13 · Cited by 353
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Miceli, M. H., & Kauffman, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ571 · Cited by 338 · cited 1×
“Renal impairment does not result in changes in the Cmax or AUC of isavuconazole, and dosage adjustment is not needed; it is likely not cleared by hemodialysis or continuous hemofiltration [97].”
Combination Treatment of Invasive Fungal Infections
Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., & Ghannoum, M. A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.1.163-194.2005 · Cited by 308
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289 · cited 1×
“lyzes the fourth enzymatic step of pyrimidine biosynthesis [110,111].”
BackgroundKawazu, M., Kanda, Y., Nannya, Y., Aoki, K., Kurokawa, M., Chiba, S., Motokura, T., Hirai, H., & Ogawa, S. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2733-2741.2004 · Cited by 280
Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review
van de Kant, K. D., van der Sande, L. J., Jöbsis, Q., van Schayck, O. C., & Dompeling, E. (2012) · Respiratory Research · doi:10.1186/1465-9921-13-117 · Cited by 252 · cited 1×
“sions in patients with suspected IPA [123].”
Duarte, R. F., Sanchez-Ortega, I., Cuesta, I., Arnan, M., Patino, B., Fernandez de Sevilla, A., Gudiol, C., Ayats, J., & Cuenca-Estrella, M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu673 · Cited by 225
Guinea, J., Peláez, T., Recio, S., Torres-Narbona, M., & Bouza, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01512-07 · Cited by 215
Lanternier, F., Mahdaviani, S. A., Barbati, E., Chaussade, H., Koumar, Y., Levy, R., Denis, B., Brunel, A.-S., Martin, S., Loop, M., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.12.1930 · Cited by 214
Bretagne, S., Costa, J., Bart–Delabesse, E., Dhedin, N., Rieux, C., & Cordonnier, C. (1998) · Clinical Infectious Diseases · doi:10.1086/516343 · Cited by 209 · cited 1×
“Initial PCR-based assays were marred by spurious results and were not more sensitive than GMA assay to detect IPA [55].”
MethodMiyazaki, T., Kohno, S., Mitsutake, K., Maesaki, S., Tanaka, K., Ishikawa, N., & Hara, K. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.12.3115-3118.1995 · Cited by 204
Mold Infections of the Central Nervous System
McCarthy, M., Rosengart, A., Schuetz, A. N., Kontoyiannis, D. P., & Walsh, T. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1216008 · Cited by 203 · cited 1×
“immunocompromised hosts, and are often associated with tissue destruction, angioinvasion, and hemoptysis [22,23].”
BackgroundSelf-citationIn Vitro Activity of E1210, a Novel Antifungal, against Clinically Important Yeasts and Molds
Miyazaki, M., Horii, T., Hata, K., Watanabe, N.-A., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., Inoue, S., Matsukura, M., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00291-11 · Cited by 200 · cited 1×
“growth, including strains resistant to triazoles and polyenes [107,108].”
BackgroundPredictors of mortality in chronic pulmonary aspergillosis
Lowes, D., Al-Shair, K., Newton, P. J., Morris, J., Harris, C., Rautemaa-Richardson, R., & Denning, D. W. (2017) · European Respiratory Journal · doi:10.1183/13993003.01062-2016 · Cited by 194
Caillot, D., Thiébaut, A., Herbrecht, R., de Botton, S., Pigneux, A., Bernard, F., Larché, J., Monchecourt, F., Alfandari, S., & Mahi, L. (2007) · Cancer · doi:10.1002/cncr.23109 · Cited by 190 · cited 1×
“We do not recommend the combination of a triazole with a polyene and do not routinely combine a polyene with an echinocandin to treat IPA [1,133].”
BackgroundSulahian, A., Tabouret, M., Ribaud, P., Sarfati, J., Gluckman, E., Latgé, J. P., & Derouin, F. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01591487 · Cited by 183 · cited 1×
“Although there have been several iterations of the GMA assay, current versions utilize a double-sandwich enzyme immunoassay and detect multiple epitopes on galactofuranose side chains of galactomannan [27,33].”
MethodUtility of Aspergillus Antigen Detection in Specimens Other than Serum Specimens
Klont, R. R., Mennink-Kersten, M. A. S. H., & Verweij, P. E. (2004) · Clinical Infectious Diseases · doi:10.1086/425317 · Cited by 182
Electronic Nose Technology in Respiratory Diseases
Dragonieri, S., Pennazza, G., Carratu, P., & Resta, O. (2017) · Lung · doi:10.1007/s00408-017-9987-3 · Cited by 179 · cited 1×
“at high throughput, and this method can be utilized to potentially diagnose pulmonary diseases [126].”
MethodSchmitt-Hoffmann, A., Roos, B., Heep, M., Schleimer, M., Weidekamm, E., Brown, T., Roehrle, M., & Beglinger, C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.279-285.2006 · Cited by 170 · cited 1×
“The prodrug isavuconazonium is rapidly converted into isavuconazole in a reaction catalyzed by plasma esterases [94].”
BackgroundEpidemiological and Genomic Landscape of Azole Resistance Mechanisms in Aspergillus Fungi
Hagiwara, D., Watanabe, A., Kamei, K., & Goldman, G. H. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01382 · Cited by 166 · cited 1×
“nidulans, as well as many other less common species, are ubiquitous in nature, and humans routinely inhale their infectious conidia [4,5].”
BackgroundAspergillus Meningitis: Diagnosis by Non-Culture-Based Microbiological Methods and Management
Verweij, P. E., Brinkman, K., Kremer, H. P. H., Kullberg, B.-J., & Meis, J. F. G. M. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.1186-1189.1999 · Cited by 159
Aguado, J. M., Vazquez, L., Fernandez-Ruiz, M., Villaescusa, T., Ruiz-Camps, I., Barba, P., Silva, J. T., Batlle, M., Solano, C., Gallardo, D., et al. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu833 · Cited by 158 · cited 1×
“with an earlier diagnosis and a lower incidence of IPA in highrisk hematological patients [100].”
BackgroundEvaluation of Aspergillus PCR Protocols for Testing Serum Specimens
White, P. L., Mengoli, C., Bretagne, S., Cuenca-Estrella, M., Finnstrom, N., Klingspor, L., Melchers, W. J. G., McCulloch, E., Barnes, R. A., Donnelly, J. P., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05316-11 · Cited by 156 · cited 1×
“for the use of PCR from whole blood and serum to diagnose IA [57,58].”
BackgroundHost-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis
Stergiopoulou, T., Meletiadis, J., Roilides, E., Kleiner, D. E., Schaufele, R., Roden, M., Harrington, S., Dad, L., Segal, B., & Walsh, T. J. (2007) · American Journal of Clinical Pathology · doi:10.1309/ujrv9dlc11rm3g8r · Cited by 152
Self-citationWalsh, T. J., Shoham, S., Petraitiene, R., Sein, T., Schaufele, R., Kelaher, A., Murray, H., Mya-San, C., Bacher, J., & Petraitis, V. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4744-4748.2004 · Cited by 151
Self-citationHata, K., Horii, T., Miyazaki, M., Watanabe, N.-A., Okubo, M., Sonoda, J., Nakamoto, K., Tanaka, K., Shirotori, S., Murai, N., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00366-11 · Cited by 149
PCR in Diagnosis of Invasive Aspergillosis: a Meta-Analysis of Diagnostic Performance
Arvanitis, M., Ziakas, P. D., Zacharioudakis, I. M., Zervou, F. N., Caliendo, A. M., & Mylonakis, E. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01365-14 · Cited by 148 · cited 1×
“considered sufficient to postpone antifungal treatment [59].”
Desai, A., Kovanda, L., Kowalski, D., Lu, Q., Townsend, R., & Bonate, P. L. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02819-15 · Cited by 143 · cited 1×
“A PPK model to identify covariates that affect isavuconazole PK has been developed to determine the probability of target attainment in IA patients [98].”
MethodSchmitt-Hoffmann, A., Roos, B., Maares, J., Heep, M., Spickerman, J., Weidekamm, E., Brown, T., & Roehrle, M. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.286-293.2006 · Cited by 141
Alvarez-Moreno, C., Lavergne, R.-A., Hagen, F., Morio, F., Meis, J. F., & Le Pape, P. (2017) · Scientific Reports · doi:10.1038/srep45631 · Cited by 141
White, P. L., Barnes, R. A., Springer, J., Klingspor, L., Cuenca-Estrella, M., Morton, C. O., Lagrou, K., Bretagne, S., Melchers, W. J. G., Mengoli, C., et al. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00905-15 · Cited by 140 · cited 1×
“National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven/ probable cases and 42 controls) [60].”
BackgroundBecker, P., Bel, A. D., Martiny, D., Ranque, S., Piarroux, R., Cassagne, C., Detandt, M., & Hendrickx, M. (2014) · Medical Mycology · doi:10.1093/mmy/myu064 · Cited by 132
Sulahian, A., Porcher, R., Bergeron, A., Touratier, S., Raffoux, E., Menotti, J., Derouin, F., & Ribaud, P. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.03567-13 · Cited by 125 · cited 1×
“(n = 91) IA, 97 hematology patients at risk for invasive fungal infections (IFIs), and 50 healthy blood donors [51].”
BackgroundArvanitis, M., Anagnostou, T., & Mylonakis, E. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ555 · Cited by 117
Donnelly, J. P. (2006) · Clinical Infectious Diseases · doi:10.1086/499818 · Cited by 114 · cited 3×
“Aspergillus PCR Initiative (EAPCRI) [56].”
InfluentialRybak, J. M., Marx, K. R., Nishimoto, A. T., & Rogers, P. D. (2015) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1652 · Cited by 101
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
Thompson, G. R., Donnelley, M., & Zhu, E. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s81416 · Cited by 99 · cited 1×
“Renal excretion is <1% of the dose administered, suggesting little utility in the treatment of fungal urinary tract infections [79].”
Pfaller, M. A., Messer, S. A., Motyl, M. R., Jones, R. N., & Castanheira, M. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01588-12 · Cited by 98
Denning, D. W., Perlin, D. S., Muldoon, E. G., Colombo, A. L., Chakrabarti, A., Richardson, M. D., & Sorrell, T. C. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2302.152042 · Cited by 95
Wattal, C., Oberoi, J. K., Goel, N., Raveendran, R., & Khanna, S. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2864-9 · Cited by 95
Wring, S. A., Randolph, R., Park, S., Abruzzo, G., Chen, Q., Flattery, A., Garrett, G., Peel, M., Outcalt, R., Powell, K., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02068-16 · Cited by 94 · cited 1×
“combination therapy, especially if it displays synergy or additivity with oral formulations of isavuconazole [137,138].”
Backgroundde Heer, K., van der Schee, M. P., Zwinderman, K., van den Berk, I. A. H., Visser, C. E., van Oers, R., & Sterk, P. J. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.02838-12 · Cited by 93 · cited 1×
“leads to a distinctive breathprint [125,127].”
Warn, P. A., Sharp, A., & Denning, D. W. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki399 · Cited by 93 · cited 1×
“new triazole, BAL4815, the active component of BAL8557 (a water-soluble prodrug), against species of Aspergillus [82].”
BackgroundReinwald, M., Hummel, M., Kovalevskaya, E., Spiess, B., Heinz, W. J., Vehreschild, J. J., Schultheis, B., Krause, S. W., Claus, B., Suedhoff, T., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks208 · Cited by 92
Critical Stages of Extracting DNA from Aspergillus fumigatus in Whole-Blood Specimens
White, P. L., Perry, M. D., Loeffler, J., Melchers, W., Klingspor, L., Bretagne, S., McCulloch, E., Cuenca-Estrella, M., Finnstrom, N., Donnelly, J. P., et al. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01466-10 · Cited by 90
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01355-13 · Cited by 88
Eigl, S., Prattes, J., Reinwald, M., Thornton, C. R., Reischies, F., Spieß, B., Neumeister, P., Zollner‐Schwetz, I., Raggam, R. B., Flick, H., et al. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.05.017 · Cited by 86
Isavuconazole: A New Option for the Management of Invasive Fungal Infections
Pettit, N. N., & Carver, P. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015581679 · Cited by 86
Schmitt‐Hoffmann, A. H., Desai, A. V., Kowalski, D. L., Pearlman, H., Yamazaki, T., & Townsend, R. W. (2016) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202434 · Cited by 86 · cited 1×
“ability of isavuconazole and the effect of food on the absorption of isavuconazole [89].”
BackgroundMasih, A., Singh, P. K., Kathuria, S., Agarwal, K., Meis, J. F. G. M., & Chowdhary, A. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00962-16 · Cited by 82
Bart–Delabesse, E., Basile, M. R., Jijakli, A. A., Souville, D., Gay, F., Philippe, B., Bossi, P., Danis, M., Vernant, J., & Datry, A. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5214-5220.2005 · Cited by 80 · cited 1×
“serve as an adjunctive test for the diagnosis of IPA [34,35].”
BackgroundDiagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis
Pan, Z., Fu, M., Zhang, J., Zhou, H., Fu, Y., & Zhou, J. (2015) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000092 · Cited by 76 · cited 11×
“The Platelia GMA assay is available for use on serum and bronchoalveolar lavage (BAL) samples and may serve as an adjunctive test for the diagnosis of IPA [34,35].”
BackgroundInfluentialShaukat, A., Bakri, F. G., Young, P. M., Hahn, T., Ball, D., Baer, M. R., Wetzler, M., Slack, J. L., Loud, P. A., Czuczman, M. S., et al. (2005) · Mycopathologia · doi:10.1007/s11046-004-5495-0 · Cited by 75
Self-citationGalactomannan antigen detection in the diagnosis of invasive aspergillosis
Verdaguer, V., Walsh, T. J., Hope, W. W., & Cortez, K. J. (2007) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.7.1.21 · Cited by 75
Self-citationThe anti-Aspergillus drug pipeline: Is the glass half full or empty?: Table 1.
Osherov, N., & Kontoyiannis, D. P. (2017) · Medical Mycology · doi:10.1093/mmy/myw060 · Cited by 74
Diagnosis of invasive fungal infections: advances in nonculture systems.
Walsh, T. J., & Chanock, S. J. (1998) · PubMed · Cited by 73
Self-citationKovanda, L. L., Desai, A. V., Lu, Q., Townsend, R. W., Akhtar, S., Bonate, P. L., & Hope, W. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00514-16 · Cited by 73 · cited 1×
“A PPK model has been constructed using nonparametric estimation to compare the PK behaviors of isavuconazole in patients with renal impairment who were treated for IA [96].”
MethodIsavuconazole: A Review in Invasive Aspergillosis and Mucormycosis
Shirley, M., & Scott, L. J. (2016) · Drugs · doi:10.1007/s40265-016-0652-6 · Cited by 73 · cited 1×
“These studies provided a pathway for approval by the FDA and the EMA for the treatment of IA [92].”
BackgroundHoenigl, M., Koidl, C., Duettmann, W., Seeber, K., Wagner, J., Buzina, W., Wölfler, A., Raggam, R. B., Thornton, C. R., & Krause, R. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.10.003 · Cited by 71 · cited 1×
“For example, an immunochromatographic lateral flow assay (LFA) for rapid point-of-care diagnosis of IA using serum or BAL samples has recently been developed [102].”
BackgroundNatesan, S. K., & Chandrasekar, P. H. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s102207 · Cited by 71
Machetti, M., Zotti, M., Veroni, L., Mordini, N., Lint, M. T. V., Bacigalupo, A. P., Paola, G. D., & Viscoli, C. (2000) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.2000.020307.x · Cited by 69
Schmitt-Hoffmann, A., Roos, B., Spickermann, J., Heep, M., Peterfaí, E., Edwards, D. J., & Stoeckel, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00319-09 · Cited by 69
Muñóz, P., Singh, N., & Bouza, E. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/01.qco.0000235164.70678.97 · Cited by 67
Reinwald, M., Spiess, B., Heinz, W. J., Vehreschild, J. J., Lass‐Flörl, C., Kiehl, M., Schultheis, B., Krause, S. W., Wolf, H., Bertz, H., et al. (2012) · European Journal of Haematology · doi:10.1111/j.1600-0609.2012.01806.x · Cited by 67
Calling upon all public health mycologists: To accompany the country burden papers from 14 countries
Denning, D. W. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2909-8 · Cited by 67 · cited 3×
“One study compared performance of the GMA assay with the BDG assay in sera from 105 patients with proven (n = 14) or probable (n = 91) IA, 97 hematology patients at risk for invasive fungal infections (IFIs), and 50 healthy blood donors [51].”
BackgroundInfluentialHeo, S. T., Tatara, A. M., Jiménez-Ortigosa, C., Jiang, Y., Lewis, R. E., Tarrand, J., Tverdek, F., Albert, N. D., Verweij, P. E., Meis, J. F., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix297 · Cited by 67
Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment
Desai, A. V., Schmitt-Hoffmann, A.-H., MUJAIS, S. K., & Townsend, R. W. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02942-15 · Cited by 66 · cited 2×
“It also has predictable pharmacokinetics (PK) in adults, has fewer drug–drug interactions than many existing antifungal agents, and is available in both oral and β-cyclodextrin-free intravenous (IV) formulations, making it an encouraging new therapy for the treatment of IPA [80,81].”
BackgroundYonetani, S., Ohnishi, H., Ohkusu, K., Matsumoto, T., & Watanabe, T. (2016) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.09.014 · Cited by 66
Guinea, J., Padilla, C., Escribano, P., Muñoz, P., Padilla, B., Gijón, P., & Bouza, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061545 · Cited by 65 · cited 1×
“neous sputum, bronchial aspirate, and BAL samples for the diagnosis of IA in patients without hematological cancer [63]”
Measurement of (1-3)-.BETA.-D-Glucan Derived from Different Gauze Types
Kanamori, H., Kanemitsu, K., Miyasaka, T., Ameku, K., Endo, S., Aoyagi, T., Inden, K., Hatta, M., Yamamoto, N., Kunishima, H., et al. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.217.117 · Cited by 63
Ibrahim, A. S., Gebremariam, T., Luo, G., Fu, Y., French, S. W., Edwards, J. E., & Spellberg, B. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01577-10 · Cited by 63
Cuétara, M. S., Alhambra, A., Moragues, M. D., González-Elorza, E., Pontón, J., & del Palacio, A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00009-09 · Cited by 62 · cited 1×
“cutoffs to optimize performance of the BDG assay to diagnose IPA have not been defined [47].”
BackgroundLivermore, J., & Hope, W. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.683859 · Cited by 62
Bronchiectasis andAspergillus: How are they linked?
Soyza, A. D., & Aliberti, S. (2016) · Medical Mycology · doi:10.1093/mmy/myw109 · Cited by 62 · cited 1×
“Chronic pulmonary aspergillosis represents a different form of pulmonary disease and includes conditions such as chronic cavitary pulmonary aspergillosis, chronic fibrosing pulmonary aspergillosis, Aspergillus nodule, simple aspergilloma, and tracheobronchial aspergillosis [3,19].”
BackgroundPrattes, J., Lackner, M., Eigl, S., Reischies, F., Raggam, R. B., Koidl, C., Flick, H., Wurm, R., Palfner, M., Wölfler, A., et al. (2015) · Mycoses · doi:10.1111/myc.12343 · Cited by 60 · cited 1×
“The antigen is an Aspergillus-specific mannoprotein that is detected by JF5 monoclonal antibodies [103].”
BackgroundAzole resistance surveillance in Aspergillus fumigatus: beneficial or biased?
Verweij, P. E., Lestrade, P. P. A., Melchers, W. J. G., & Meis, J. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw259 · Cited by 59
Johnson, G. L., Sarker, S., Nannini, F., Ferrini, A., Taylor, E., Lass‐Flörl, C., Mutschlechner, W., Bustin, S. A., & Agrawal, S. G. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00110-15 · Cited by 57 · cited 11×
“The Platelia GMA assay is available for use on serum and bronchoalveolar lavage (BAL) samples and may serve as an adjunctive test for the diagnosis of IPA [34,35].”
BackgroundInfluentialHollomon, D. (2017) · Pest Management Science · doi:10.1002/ps.4607 · Cited by 57
Design Issues in Studies Evaluating Diagnostic Tests for Aspergillosis
Marr, K. A., & Leisenring, W. M. (2005) · Clinical Infectious Diseases · doi:10.1086/430920 · Cited by 55 · cited 1×
“serve as an adjunctive test for the diagnosis of IPA [34,35].”
BackgroundInvasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
Arthurs, B., Wunderle, K., Hsu, M., & Kim, S. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.03.011 · Cited by 54
The first echinocandin: caspofungin: Das erste Echinocandin: Caspofungin
Cornely, O. A., Schmitz, K., & Aisenbrey, S. (2002) · Mycoses · doi:10.1111/j.1439-0507.2002.tb04771.x · Cited by 53 · cited 1×
“Threemajor classes of antifungal agents are available to treat IPA: triazoles, echinocandins, and polyenes [74,75].”
Backgroundde Heer, K., Kok, M. G. M., Fens, N., Weersink, E. J. M., Zwinderman, A. H., van der Schee, M. P. C., Visser, C. E., van Oers, M. H. J., & Sterk, P. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02214-15 · Cited by 53 · cited 2×
“leads to a distinctive breathprint [125,127].”
BackgroundPfaller, M. A., Watanabe, N., Castanheira, M., Messer, S. A., & Jones, R. N. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr342 · Cited by 50 · cited 1×
“growth, including strains resistant to triazoles and polyenes [107,108].”
BackgroundAstvad, K. M. T., Hare, R. K., & Arendrup, M. C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.03.023 · Cited by 48
PCR methodology and applications for the detection of human fungal pathogens
McCarthy, M. W., & Walsh, T. J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1219253 · Cited by 47
Self-citationIsavuconazole as salvage therapy for mucormycosis
Graves, B., Morrissey, C. O., Wei, A. H., Coutsouvelis, J., Ellis, S. J., Pham, A., Gooi, J. H., & Ananda-Rajah, M. R. (2016) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2016.03.002 · Cited by 45
Evaluation of the (1,3)-β-D-glucan assay for the diagnosis of neonatal invasive yeast infections
Cornu, M., Goudjil, S., Kongolo, G., Leke, A., Poulain, D., Chouaki, T., & Sendid, B. (2017) · Medical Mycology · doi:10.1093/mmy/myx021 · Cited by 44
Hoenigl, M., Seeber, K., Koidl, C., Buzina, W., Wölfler, A., Duettmann, W., Wagner, J., Strenger, V., & Krause, R. (2013) · Mycoses · doi:10.1111/myc.12060 · Cited by 42
Katragkou, A., McCarthy, M., Meletiadis, J., Petraitis, V., Moradi, P. W., Strauss, G. E., Fouant, M. M., Kovanda, L. L., Petraitiene, R., Roilides, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03261-14 · Cited by 42
Self-citationApplication of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections
Mery, A., Sendid, B., François, N., Cornu, M., Poissy, J., Guerardel, Y., & Poulain, D. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01655-16 · Cited by 41
Polar Extremes in the Clinical Use of Stem Cells
Daley, G. Q. (2017) · New England Journal of Medicine · doi:10.1056/nejme1701379 · Cited by 40
Kovanda, L. L., Petraitienė, R., Petraitis, V., Walsh, T. J., Desai, A. V., Bonate, P. L., & Hope, W. W. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw098 · Cited by 35 · cited 2×
“cant relationship between race and clearance [93].”
BackgroundSelf-citationAre allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions?
Agarwal, R., Bansal, S., & Chakrabarti, A. (2016) · Medical Mycology · doi:10.1093/mmy/myw071 · Cited by 32
Desai, A. V., Yamazaki, T., Dietz, A. J., Kowalski, D. L., Lademacher, C., Pearlman, H., Akhtar, S., & Townsend, R. W. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.283 · Cited by 30 · cited 1×
“It also has predictable pharmacokinetics (PK) in adults, has fewer drug–drug interactions than many existing antifungal agents, and is available in both oral and β-cyclodextrin-free intravenous (IV) formulations, making it an encouraging new therapy for the treatment of IPA [80,81].”
BackgroundIdelevich, E. A., Grünastel, B., & Becker, K. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.01787-16 · Cited by 30
Leonardelli, F., Theill, L., Nardin, M. E., Macedo, D., Dudiuk, C., Méndez, E., Gamarra, S. P., & García‐Effrón, G. (2017) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.05.005 · Cited by 30
New pharmacological opportunities for the treatment of invasive mould diseases
Ledoux, M., Toussaint, E., Denis, J., & Herbrecht, R. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx033 · Cited by 30
Borlenghi, E., Cattaneo, C. M., Capucci, M. A., Pan, A., Quaresmini, G., Franco, F., Grazioli, L., Carosi, G. P., & Rossi, G. (2006) · Annals of Hematology · doi:10.1007/s00277-006-0204-3 · Cited by 29
The current management landscape: aspergillosis: Table 1.
Maertens, J. A., Blennow, O., Duarte, R. F., & Muñoz, P. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw393 · Cited by 29 · cited 1×
“However, treatment failure is not uncommon, and some patients are intolerant of voriconazole and amphotericin B, which underscores the need for novel treatment options [76].”
BackgroundCombination Antifungal Therapy for Invasive Aspergillosis Revisited
Panackal, A. A. (2016) · Medical Mycology Open Access · doi:10.21767/2471-8521.100012 · Cited by 28
Nakamura, S., Sato, H., Tanaka, R. J., Kusuya, Y., Takahashi, H., & Yaguchi, T. (2017) · BMC Microbiology · doi:10.1186/s12866-017-1009-3 · Cited by 23 · cited 1×
“population-based, species-specific therapeutic guidelines for IPA [70].”
de Heer, K., Vonk, S. I., Kok, M. G. M., Kolader, M. E., Zwinderman, A. H., van Oers, M. H. J., Sterk, P. J., & Visser, C. E. (2016) · Journal of Breath Research · doi:10.1088/1752-7155/10/3/036008 · Cited by 22
Diagnostic Criteria for Invasive Pulmonary Aspergillosis in Critically Ill Patients
Azoulay, É., & Afessa, B. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0761ed · Cited by 20
Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?
Katragkou, A., Roilides, E., & Walsh, T. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1186647 · Cited by 19
Self-citationTriazole Resistance in Aspergillus fumigatus Clinical Isolates Obtained in Nanjing, China
Zhang, M., Feng, C., Chen, F., He, Q., Su, X., & Shi, Y. P. (2017) · Chinese Medical Journal · doi:10.4103/0366-6999.201609 · Cited by 19
Aslan, M., Öz, Y., Akşit, F., & Akay, O. M. (2015) · Mycoses · doi:10.1111/myc.12322 · Cited by 18 · cited 1×
“keted real-time PCR assay for detection of Aspergillus DNA in lower respiratory tract samples [61,62].”
MethodDie allergische bronchopulmonale Aspergillose (ABPA)
Menz, G., Willer, G., & Crameri, R. (2000) · Pneumologie · doi:10.1055/s-2000-7187 · Cited by 18
Hypersensitivity pneumonitis: The dug-well lung
Sharma, B. B., Singh, S., & Singh, V. (2013) · Allergy and Asthma Proceedings · doi:10.2500/aap.2013.34.3709 · Cited by 14
Öz, Y., Aslan, M., Akşit, F., Metintaş, S., & Gündüz, E. (2015) · Mycoses · doi:10.1111/myc.12438 · Cited by 14 · cited 1×
“keted real-time PCR assay for detection of Aspergillus DNA in lower respiratory tract samples [61,62].”
MethodInvasive Aspergillosis in Hematological Patients
Kimura, S.-I. (2016) · Medical Mycology Journal · doi:10.3314/mmj.57.j77 · Cited by 14 · cited 1×
“Threemajor classes of antifungal agents are available to treat IPA: triazoles, echinocandins, and polyenes [74,75].”
BackgroundDiagnosis, classification, and therapeutic interventions for sinopulmonary Aspergillosis
McCarthy, M. W., Aguilar-Zapata, D., Petraitis, V., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1283986 · Cited by 11 · cited 3×
“Alternative treatments include both liposomal amphotericin B and lipid formulations of amphotericin B [1].”
BackgroundSelf-citationNucleic acid amplification methodologies for the detection of pulmonary mold infections
McCarthy, M. W., Petraitienė, R., & Walsh, T. J. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1293528 · Cited by 11
Self-citationInvasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis
Aguado, D. M., Ballester, M. P., & Boscá-Watts, M. M. (2017) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2017.4564/2016 · Cited by 11 · cited 1×
“in combination with the histopathologic demonstration of pulmonary invasion by hyphae provides definitive evidence of IPA [12,13].”
BackgroundAllergic Bronchopulmonary Aspergillosis: AllA Radiologist Needs To Know
Garg, M. K., Sharma, M., Agarwal, R., Aggarwal, A. N., Gupta, P., Sodhi, K. S., Chakrabarti, A., & Khandelwal, N. K. (2016) · Current Pediatric Reviews · doi:10.2174/1573396312666160831143951 · Cited by 10
Die allergische bronchopulmonale Aspergillose (ABPA)
Menz, G., Hense, G., & Willer, G. (2003) · Pneumologie · doi:10.1055/s-2003-40553 · Cited by 9
Fernandes, L. (2016) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2016/16674.7133 · Cited by 7
Case Series Study of Invasive Pulmonary Aspergillosis
Aller, A. I., Méndez, C. C., Alastruey‐Izquierdo, A., Marín-Martínez, E. M., Breval, I. Z.-Y., Couto-Caro, C., López-Marín, J. C., Peña-Griñán, N., de Pipaón, M. R. P., Mejías, A. R., et al. (2016) · Mycopathologia · doi:10.1007/s11046-016-0097-1 · Cited by 5 · cited 2×
“appropriate specimen is often infeasible in clinical practice because many at-risk patients are thrombocytopenic and thus unable to undergo biopsy [27].”
BackgroundMethodInvasive pulmonary aspergillosis in a steroid-dependent asthmatic
Jaumally, B. A., Salem, A. M., Sagar, A.-E. S., & Pyrgos, G. J. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.02.007 · Cited by 3 · cited 1×
“in combination with the histopathologic demonstration of pulmonary invasion by hyphae provides definitive evidence of IPA [12,13].”
BackgroundDedekargınoğlu, B. E., Bozbaş, Ş. S., Ulubay, G., Eyüboğlu, F. Ö., & Haberal, M. A. (2017) · Experimental and Clinical Transplantation · doi:10.6002/ect.mesot2016.p91 · Cited by 3
Machetti, M., & Viscoli, C. (2006) · PubMed · Cited by 2
Research works printed but not linked: 14
- Jaumally BA, 2017, Respir Med Case Rep, 20, 156
- Agarwal R, 2016, Med Mycol, 87
- Fernandes L, 2016, J Clin Diagn Res, 10, OD16
- Machetti M, 2006, Infez Med, 14, 197
- Walsh TJ, 1998, Curr Clin Top Infect Dis, 18, 101
- Cruciani M, 2015, Cochrane Database Syst Rev, 10, CD009551
- Donnelley MA, 2016, Infect Drug Resist, 9, 79
- Desai A, 2016, Clin Pharmacol Drug Dev, 9, 291
- Law D, 2016, The efficacy of F901318 a novel antifungal drug in an animal model of aspergillosis
- Arthurs B, 2017, Respir Med Case Rep, 21, 27
- Er Dedekarginoglu B, 2017, Exp Clin Transplant, 15, 214
- Hollomon D, 2017, Pest Manag Sci, 12, 412
- Astvad KM, 2017, Clin Microbiol Infect, 32, 311
- 10.1128/AAC.02068-16 · DOI · Paper page
Cited by
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
“In these patients, with impaired immune function, Aspergillus growth in the lung leads to tissue destruction, angio-invasion, a septic state in its final phase and sometimes haemoptysis [98].”
BackgroundInvasive pulmonary aspergillosis in the intensive care unit: current challenges and best practices
Gaffney, S. M., Kelly, D., Rameli, P. M., Kelleher, E. M., & Martín‐Loeches, I. (2023) · Apmis · doi:10.1111/apm.13316 · Cited by 51
“The clinical presentation is relatively rapid, ranging from days to weeks (16).”
BackgroundUnderstanding the environmental drivers of clinical azole resistance in Aspergillus species
Sen, P., Vijay, M., Singh, S., Hameed, S., & Vijayaraghavan, P. (2022) · Drug Target Insights · doi:10.33393/dti.2022.2476 · Cited by 41
“Invasion of the lungs by Aspergillus leads to tissue damage leading to sepsis and sometimes haemoptysis in later stages (11).”
BackgroundCarbohydrate Specificity of Antibodies against Phytopathogenic Fungi of the Aspergillus Genus
Krylov, V. B., Петрук, М. И., Глушко, Н. И., Khaldeeva, E. V., Мокеева, В. Л., Биланенко, Е. Н., Lebedin, Y. S., Еремин, С. А., & Nifantiev, N. E. (2018) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683818050095 · Cited by 10
Corrêa-Almeida, C., Borba-Santos, L. P., Rollin‐Pinheiro, R., Barreto‐Bergter, E., Rozental, S., & Kurtenbach, E. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.795255 · Cited by 8
Metadata
- Authors
- McCarthy, M. W., & Walsh, T. J.
- Affiliations
- Cornell University (US)
- Weill Cornell Medical Center (US)
- Corresponding author
- McCarthy, Matthew William
- Venue
- Expert Review of Respiratory Medicine
- Publisher
- Informa UK Limited
- Published
- 2017-06-21
- Volume
- 11
- Issue
- 9
- Pages
- 739-748
- ISSN
- 1747-6348 (ISSN-L)
- 1747-6356
- OpenAlex
- W2623020088
- Cited by
- 8
- References
- 137
- Citations by year
- 2025: 1 · 2023: 1 · 2022: 4 · 2018: 1 · 2017: 1
- FWCI
- 0.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Respiratory Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- invasive pulmonary aspergillosis, Aspergillus, immunocompromised patients, diagnostic methods, multiplex PCR, MALDI-TOF mass spectrometry, isavuconazole, triazoles, lateral flow assay, volatile organic compounds, antifungal agents, prophylaxis
- MeSH terms
- Antifungal Agents, Humans, Nitriles, Pyridines, Triazoles, Immunocompromised Host, Treatment Outcome, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Invasive Pulmonary Aspergillosis, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.